Mr. Day is a commercial development specialist, whose primary focus and expertise is the dermatology marketplace. He has held strategic sales, marketing, and management positions with major pharmaceutical companies, including Allergan Pharmaceuticals and Ferndale Laboratories. In 2000, Mr. Day founded Rx-Pharma Pharmaceuticals, Inc., a specialty pharmaceutical business with two licensed products ("Pandel" and "Pro-Q") and a delivery platform technology, "Restoraderm." After building a sales force and developing several products utilizing the Restoraderm platform, he successfully negotiated and consummated the sale of Rx-Pharma to CollaGenex Pharmaceuticals, Inc., assuming the position of Vice President, Dermatology at CollaGenex. A key to Mr. Day's success in the pharmaceutical industry is his strong ongoing relationships with the members of the dermatology community and capitalizing on their experience and expertise during the development, launch, and sales of new products. These ongoing working relationships are the basis for building invaluable Advisory Boards, and Steering Committees and aid tremendously in the successful launch of unique prescription drug products.
Prior to joining Quinnova Pharmaceuticals, Inc. Mr. Napolitana was Vice President Finance of Bilcare, Inc. a Clinical Supplies and Services company. He established the financial, information technology and purchasing functions for this new US subsidiary of an international parent company. He also helped lead the identification, acquisition and integration of a European subsidiary in Wales. Mr. Napolitana also brings over 15+ years of senior level financial experience with Fortune 500 companies such as Cardinal Health and Fisher Scientific. In these various roles Mr. Napolitana developed expertise in manufacturing and distribution operations along with financial controls and systems implementation and development.
Mr. Schloeffel has more than 15 years of sales and sales management related experience in the medical and pharmaceutical industry. He began his career with Johnson & Johnson in their Diagnostic Hospital Division and progressed to a specialty sales position. He joined Ferndale Laboratories, a specialty pharmaceutical company in 1997 and advanced quickly into a Regional Sales Director. During his tenure with Ferndale Laboratories, Mr. Schloeffel has been part of more than 7 new OTC and branded prescription drug product launches and built multiple sales teams as the company grew from 14 to 80 sales representatives across the country. He has expertise in building new sales forces and sales management teams and related operations, optimizing sales performance, as well as overseeing sales force training. Mr. Schloeffel is a Navy veteran with 21 years of service, retiring from the Naval Reserves in 2001.
Dr. van den Woldenberg has held strategic sales, marketing, business development and management positions with major pharmaceutical companies in Europe and the US, including Hoechst, Hoechst Marion Roussel, Aventis, inVentiv as well as Bradley Pharmaceuticals. His major achievements include the successful launch of Levofloxacin (Elequin, Levaquin, TAVANIC) in Europe and Latin America, the establishment of a global strategic forecasting process for products in development (pre-clinical - clinical - phase II) for Hoechst Marion Roussel and the development and introduction of AnaMantle HC for Bradley Pharmaceuticals. Dr. van den Woldenberg has extensive experience in identifying potential drug candidates and successfully commercializing them. Dr. van den Woldenberg is a trained veterinarian with a Ph.D. in virology.